about
An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adultsAcupuncture for migraine prophylaxisImpact of headache in Europe: a review for the Eurolight projectAcupuncture for the prevention of episodic migraineIs There Any Scientific Basis of Hawan to be used in Epilepsy-Prevention/Cure?Investing in mental health and well-being: findings from the DataPrev projectHomocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendationsStroke: working toward a prioritized world agendaStroke: working toward a prioritized world agendaStroke: working toward a prioritized world agendaProgressive and self-limiting neurodegenerative disorders in Africa: a new prominent field of research led by South Africa but without strong health policy.Schoolchildren, maternal nutrition and generating healthy brains: the importance of lifecycle education for fertility, health and peace.The clinical implications of mouse models of enhanced anxiety.Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.The migrainous brain: what you see is not all you get?Costs of treating patients with schizophrenia who have illness-related crisis eventsUptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries.The cost of relapse and the predictors of relapse in the treatment of schizophreniaThe effectiveness of Orem's self-care program on headache-related disability in migraine patients.Pattern of healthcare resource utilization and direct costs associated with manic episodes in SpainRecognition of physiotherapists' expertise in Parkinson's disease.Mental disorder and caregiver burden in spouses: the Nord-Trøndelag health study.3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders.Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case.Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.Public spending for illegal drug and alcohol treatment in hospitals: an EU cross-country comparisonCost of disorders of the brain in Spain.An examination of serotonin and psychological variables in the relationship between exercise and mental health.Diencephalic and brainstem mechanisms in migraine.Direct cost associated with acquired brain injury in Ontario.Economic burden of stroke in a large county in SwedenComorbidities of migraine.Meta-analysis of emotion recognition deficits in major depressive disorderDisease identification based on ambulatory drugs dispensation and in-hospital ICD-10 diagnoses: a comparisonAlmotriptan and zolmitriptan in the acute treatment of migraine.Including information about co-morbidity in estimates of disease burden: results from the World Health Organization World Mental Health SurveysPramipexole for the treatment of early Parkinson's disease.Estimation of the cost of MS in Europe: extrapolations from a multinational cost study.
P2860
Q22241952-5B2BA87C-34B3-4046-B028-284D5D775663Q24194364-1B04F096-B626-4069-AE0D-F76F210919DDQ24241053-5C792BF5-4E99-4D99-8D10-486DA1240390Q24654015-03155FF7-8C2C-4DE4-9FBB-E868211CB0FEQ26471421-4C85E670-CDE9-41E5-BF20-9ADDE83493D2Q26773075-92813447-25A7-470E-89AA-1AC4C52A8E81Q27001072-2DCD2209-6EAA-48FD-A18D-062FD885DCA6Q28259237-B262A9C7-2733-460A-9799-80864F373B20Q28677503-AB3EE9DA-0643-4550-A72B-7190026A939CQ28677657-3D93A31B-EE4B-4CEB-8216-09AC71657A72Q28742458-C38E259D-A71A-4F1E-89B6-47A5457500FCQ30061896-D40FD79D-77BB-469A-A27E-D31527337236Q30375831-5338D889-8490-49C6-8B83-CBF8B176C591Q30474232-83F0A87E-F0EB-450B-9F64-3115C065565BQ30846961-CE9D60AC-E4B4-47D0-8DE3-61345AD7611DQ31067806-4280253E-D0E3-4222-8A57-2E2B189DAAB8Q33363460-ECF58761-D6F2-4012-9570-1855B8B5A6F1Q33495327-F85A7A71-5250-421F-862C-7125043F01CFQ33522776-25795A06-C5D7-4DBE-A997-20964A2CE9F1Q33566295-4F9D5F34-27DD-42C6-8EBB-F95E1DE61DABQ33567174-9A52E145-8A92-40FD-8EAE-016D3BEA4A62Q33592332-FEE1E380-262A-469A-93FD-EC710EE22F1EQ33675447-155509A6-8DA9-4965-B1CB-7179088B1F3BQ33778302-8A3E21F3-147B-4678-86D6-4EA1D101C970Q33814389-7EB92FB9-5E33-4A84-9EDD-137598DCD00DQ33829034-2535ACB4-749F-4B84-BFA1-0278A7459978Q33840320-0D70AF40-C802-4C65-828E-07ECE654EFC7Q33851333-FEBBD544-BECA-4E01-BE0A-7600F0A6CBECQ34062070-C102AD6A-D7B9-4F78-AD0B-B7121C7A8EE4Q34089675-A0176115-3B95-4026-BCDB-725897A0DC79Q34217686-821345FF-3B45-463C-B040-6956821E98E0Q34383280-2DABB3A2-89C9-43C4-ADBB-92A40E239200Q34421858-20EC6D48-513C-42E7-8B75-A3A7D5BFE8B2Q34435159-F0F1D1F5-3CE5-4D11-8DF3-C2EFFC2FC777Q34447795-55BD29D4-C11A-4488-84B2-18DD574EAB27Q34493849-DCF77A64-193F-41E2-9599-A46ABF356C64Q34573136-A05AEB80-6B89-4D6E-9640-EA01F4E78476Q34608645-31149231-ABBD-41DF-85D2-B4564E20DC1BQ34630735-FFDE1B5E-B111-4956-A47C-4662271773B9Q34648681-00969648-1E4C-4AE2-B763-6E2D29AE6A1E
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cost of disorders of the brain in Europe.
@ast
Cost of disorders of the brain in Europe.
@en
type
label
Cost of disorders of the brain in Europe.
@ast
Cost of disorders of the brain in Europe.
@en
prefLabel
Cost of disorders of the brain in Europe.
@ast
Cost of disorders of the brain in Europe.
@en
P1476
Cost of disorders of the brain in Europe.
@en
P2093
Bengt Jönsson
Patrik Andlin-Sobocki
P356
10.1111/J.1468-1331.2005.01202.X
P478
12 Suppl 1
P577
2005-06-01T00:00:00Z